Thomas Morel

1.4k total citations
32 papers, 634 citations indexed

About

Thomas Morel is a scholar working on Economics and Econometrics, Neurology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Thomas Morel has authored 32 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Economics and Econometrics, 10 papers in Neurology and 6 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Thomas Morel's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Parkinson's Disease Mechanisms and Treatments (7 papers) and Pharmaceutical Economics and Policy (7 papers). Thomas Morel is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Parkinson's Disease Mechanisms and Treatments (7 papers) and Pharmaceutical Economics and Policy (7 papers). Thomas Morel collaborates with scholars based in Belgium, United States and United Kingdom. Thomas Morel's co-authors include Stefan Cano, Steven Simoens, Antoine Regnault, Babak Boroojerdi, Juliette Meunier, Massimo Bani, David Cassiman, P.D. Siviero, Francis Arickx and Entela Xoxi and has published in prestigious journals such as Neurology, Nature Reviews Drug Discovery and Annals of the Rheumatic Diseases.

In The Last Decade

Thomas Morel

31 papers receiving 613 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Morel Belgium 11 249 159 81 63 58 32 634
Catharina E. Jacobi Netherlands 15 54 0.2× 72 0.5× 153 1.9× 27 0.4× 37 0.6× 19 901
Sandra Nestler-Parr United States 4 140 0.6× 25 0.2× 216 2.7× 70 1.1× 46 0.8× 6 562
Георги Искров Bulgaria 17 312 1.3× 18 0.1× 204 2.5× 108 1.7× 55 0.9× 64 778
Nathalie McIntosh United States 15 81 0.3× 87 0.5× 112 1.4× 130 2.1× 63 1.1× 42 894
K. P. Srinath United States 12 80 0.3× 49 0.3× 226 2.8× 63 1.0× 112 1.9× 17 803
William Tillett United Kingdom 23 66 0.3× 25 0.2× 47 0.6× 15 0.2× 55 0.9× 160 2.1k
Karriem S. Watson United States 14 46 0.2× 30 0.2× 52 0.6× 31 0.5× 103 1.8× 71 562
Vivian Herrera United States 16 99 0.4× 22 0.1× 18 0.2× 33 0.5× 59 1.0× 44 780
Antoine Vanier France 16 64 0.3× 92 0.6× 23 0.3× 12 0.2× 23 0.4× 36 805
Richard Walton Australia 17 77 0.3× 44 0.3× 13 0.2× 27 0.4× 47 0.8× 53 809

Countries citing papers authored by Thomas Morel

Since Specialization
Citations

This map shows the geographic impact of Thomas Morel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Morel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Morel more than expected).

Fields of papers citing papers by Thomas Morel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Morel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Morel. The network helps show where Thomas Morel may publish in the future.

Co-authorship network of co-authors of Thomas Morel

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Morel. A scholar is included among the top collaborators of Thomas Morel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Morel. Thomas Morel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Regnault, Antoine, et al.. (2024). Clinical meaningfulness and psychometric robustness of the MG Symptoms PRO scales in clinical trials in adults with myasthenia gravis. Frontiers in Neurology. 15. 1368525–1368525. 2 indexed citations
3.
Krishna, Rajesh, Anneliene Hechtelt Jonker, Thomas Morel, et al.. (2024). IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases. Nature Reviews Drug Discovery. 24(4). 233–234. 3 indexed citations
4.
Morel, Thomas, et al.. (2023). The value of co-creating a clinical outcome assessment strategy for clinical trial research: process and lessons learnt. Research Involvement and Engagement. 9(1). 98–98. 5 indexed citations
5.
Regnault, Antoine, et al.. (2023). Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO. Neurology and Therapy. 12(5). 1573–1590. 12 indexed citations
6.
Cleanthous, Sophie, John Andrejack, William S. Brooks, et al.. (2023). Plain language summary: what symptoms should be measured in clinical studies for early-stage Parkinson's?. Future Neurology. 18(1). 1 indexed citations
7.
Morel, Thomas, Sophie Cleanthous, John Andrejack, et al.. (2023). Development and early qualitative evidence of two novel patient-reported outcome instruments to assess daily functioning in people with early-stage Parkinson’s. Journal of Patient-Reported Outcomes. 7(1). 40–40. 7 indexed citations
8.
Nicod, Elena, Andrew Lloyd, Thomas Morel, et al.. (2022). Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments. Patient. 16(1). 7–17. 8 indexed citations
9.
Cleanthous, Sophie, Sabine Bongardt, Patrick Marquis, et al.. (2021). Psychometric Analysis from EMBODY1 and 2 Clinical Trials to Help Select Suitable Fatigue PRO Scales for Future Systemic Lupus Erythematosus Studies. Rheumatology and Therapy. 8(3). 1287–1301. 9 indexed citations
10.
Cleanthous, Sophie, Ann‐Christin Mörk, Antoine Regnault, et al.. (2021). Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet Journal of Rare Diseases. 16(1). 12 indexed citations
11.
Regnault, Antoine, Babak Boroojerdi, Juliette Meunier, et al.. (2019). Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohort. Journal of Neurology. 266(8). 1927–1936. 119 indexed citations
12.
Nestler-Parr, Sandra, Mondher Toumi, Chris L. Pashos, et al.. (2018). Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health. 21(5). 493–500. 84 indexed citations
13.
Pauwels, Kim, Isabelle Huys, Minne Casteels, et al.. (2017). Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012. Orphanet Journal of Rare Diseases. 12(1). 36–36. 7 indexed citations
14.
Morel, Thomas & Stefan Cano. (2017). Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures. Orphanet Journal of Rare Diseases. 12(1). 171–171. 111 indexed citations
15.
16.
Picavet, Eline, Thomas Morel, David Cassiman, & Steven Simoens. (2014). Shining a light in the black box of orphan drug pricing. Orphanet Journal of Rare Diseases. 9(1). 62–62. 39 indexed citations
17.
18.
Morel, Thomas, et al.. (2013). Are orphan drug companies the pick of the pharmaceutical industry?. Nature Reviews Drug Discovery. 13(1). 10–10. 8 indexed citations
19.
Morel, Thomas, et al.. (2013). Managed Entry Agreements and Orphan Drugs: A European Comparative Study (2006-2012). Value in Health. 16(7). A391–A391. 4 indexed citations
20.
Garcı́a, Alberto, et al.. (2008). 177: Lessons Learned in a Colombian Civil Hospital About the Management of Patients Injured By Landmines. Annals of Emergency Medicine. 51(4). 524–524. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catharina E. Jacobi Breakdown of academic impact, for papers by Sandra Nestler-Parr Breakdown of academic impact, for papers by Георги Искров Breakdown of academic impact, for papers by Nathalie McIntosh Breakdown of academic impact, for papers by K. P. Srinath Breakdown of academic impact, for papers by William Tillett Breakdown of academic impact, for papers by Karriem S. Watson Breakdown of academic impact, for papers by Vivian Herrera Breakdown of academic impact, for papers by Antoine Vanier Breakdown of academic impact, for papers by Richard Walton
Rankless by CCL
2026